Clinical Trials Logo

Filter by:
NCT ID: NCT04722250 Active, not recruiting - Clinical trials for Aortic Valve Stenosis

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

SMART
Start date: April 2, 2021
Phase: N/A
Study type: Interventional

The purpose of this trial is to generate clinical evidence on valve safety and performance of self-expanding (SE) versus balloon-expandable (BE) transcatheter aortic valve replacement (TAVR) in subjects with a small aortic annulus and symptomatic severe native aortic stenosis. Additionally, a stress echocardiography sub-study will be conducted as part of the SMART Trial at select sites. The purpose of the sub-study is to evaluate performance of SE versus BE TAVR in subjects with a small aortic annulus and symptomatic severe native aortic stenosis after undergoing exercise stress echocardiographic testing.

NCT ID: NCT04720157 Active, not recruiting - Prostatic Neoplasms Clinical Trials

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

PSMAddition
Start date: June 9, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries.

NCT ID: NCT04717154 Active, not recruiting - Clinical trials for Prostatic Neoplasms, Castration-Resistant

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

INSPIRE
Start date: January 19, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of 4 cycles of combinatory immunotherapy (ipilimumab and nivolumab), followed by monotherapy nivolumab in participants with immunogenic metastatic castration-resistant prostate cancer.

NCT ID: NCT04716582 Active, not recruiting - Sedentary Behavior Clinical Trials

The Effect of Different Ways of Sitting on Cognitive Performance and Muscle Activity

Start date: June 7, 2019
Phase: N/A
Study type: Interventional

Academic educations concurs with a lot of sitting. Studies have shown that prolonged sitting not only has disruptive effects on physical health, but also influence mental health and cognition negatively. For physical health evidence grows that short light intense interruptions of sitting time effectively counterbalance the impact of prolonged sitting. It is not clear of light intense physical activity breaks have a similar positive effect on cognitive performance. Also, it is unclear whether cognitive loading might be able to compensate the impact of prolonged sitting.This study compares the effects of uninterrupted sitting with or without cognitive loading and interrupted sitting on cognitive functioning; muscle activation of leg and trunk muscles under various modes of sitting with walking, in order to calibrate the physical impact of different sitting modes.

NCT ID: NCT04715438 Active, not recruiting - Cancer Clinical Trials

Vaccination Against COVID-19 in Cancer

VOICE
Start date: January 8, 2021
Phase: N/A
Study type: Interventional

This study will collect information on immune response and adverse events after vaccination against coronavirus disease (COVID-19) in a vulnerable patient cohort. Understanding the ability or disability to mount a protective immune response after vaccination will help to counsel patients during the pandemic and support decisions on whom to vaccinate and to identify patients who require other measures to protect them from COVID-19.

NCT ID: NCT04711954 Active, not recruiting - Covid19 Clinical Trials

HIV/COV in Ukraine-NL

Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

Contradicting preliminary results are available on the impact of COVID-19 in people with HIV (PWH). How achieving goals of the HIV 90-90-90 cascade of care influences the risk of COVID-19 in PWH is unclear. The primary objective is to determine the impact of COVID-19 in PWH cohorts from Ukraine and the Netherlands.

NCT ID: NCT04706715 Active, not recruiting - Clinical trials for Metastatic Solid Tumor

LAG3 PET Imaging in Advanced Solid Tumors

Start date: January 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.

NCT ID: NCT04703192 Active, not recruiting - Clinical trials for Relapsed/Refractory Peripheral T-Cell Lymphoma

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Start date: June 3, 2021
Phase: Phase 2
Study type: Interventional

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

NCT ID: NCT04702737 Active, not recruiting - Clinical trials for Neuroendocrine Prostate Cancer

A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

DeLLpro-300
Start date: June 10, 2021
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

NCT ID: NCT04697628 Active, not recruiting - Cervical Cancer Clinical Trials

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

innovaTV 301
Start date: February 22, 2021
Phase: Phase 3
Study type: Interventional

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.